Progestins are a group of substances with a wide range of applications. They are classified into pregnanes, estranes, and gonanes, and further divided into four generations based on their testosterone (TE) or progesterone (P4) origin. This study reviews the existing literature on the clinical use of progestins. A literature review was conducted by PubMed, Google Scholar, Scopus and ClinicalTrials. The following search terms and their combinations were used when reviewing the aforementioned databases: (progestogen OR progestogens OR progestin OR progestins) AND (women OR woman OR men OR man OR adult). The analyzed publications about progestins were dated from 2005 to 2024. Progestins are used in both women and men, either alone (progestin-only contraception, POC) or combined with other substances (combined hormonal contraception, CHC). They are primarily used for contraception but also offer therapeutic benefits for conditions like abnormal uterine bleeding, endometriosis, secondary amenorrhea, infertility, and endometrial hyperplasia. In women with a uterus, balancing progestin with estrogen is crucial to prevent endometrial cancer. Progestins are also used in menopausal hormone therapy (MHT) to alleviate menopausal symptoms and can help prevent premature deliveries. Ongoing clinical trials are exploring their broader potential. Progestins have diverse therapeutic uses, with promising applications in various diseases. However, off-label use may present legal risks for healthcare providers, highlighting the need for clearer guidelines, particularly in non-gynecological treatments.
1 February 2008 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Introduction and Objective. For a long time, radical surgery was the standard treatment for cervical cancer. In earlystage disease, hysterectomy with lymphadenectomy was commonly performed, which forever precluded any procreative plans. The increasing number of newly-diagnosed cervical cancer cases among women of reproductive age has led to the development of fertility-preserving treatments and minimally invasive techniques. Review Methods. The review outlines fertility-sparing treatment options for patients of childbearing age diagnosed with cervical cancer. PubMed and Google Scholar (2016-2024) were searched using the terms: cervical cancer, fertility sparing treatment, fertility preservation, trachelectomy, radical trachelectomy, neoadjuvant chemotherapy, cervical cancer treatment, conization and simple trachelectomy from 5 March-28 March 2025. Original papers, literature review, case reports, randomized clinical trials and meta-analysis were included. Manuscripts not written in English were excluded excluded. Brief description of the state of knowledge. Depending on the stage of the cancer, options such as conization, trachelectomy, or neoadjuvant chemotherapy can help preserve fertility while avoiding radical procedures. The methods are evaluated for oncological outcomes, including metastasis and recurrence, and for reproductive outcomes, such as pregnancy. Summary. The review presents current fertility-sparing surgical methods as well as chemotherapeutic approaches used to preserve fertility in women undergoing treatment for cervical cancer, the outcomes and eligibility criteria. The growing clinical relevance of fertility preservation underscores its increasing role in individualized treatment planning for cervical cancer patients.
Background: Ovarian cancer remains one of the most lethal gynecologic malignancies, ranking eighth in both incidence and mortality among women. Its asymptomatic early course and nonspecific symptoms often lead to late-stage diagnosis and a poor prognosis.Aim of the study: The aim of this article is to present the current status of immunotherapy in the treatment of ovarian cancer.Material and methods: A narrative review of the available literature was conducted, focusing on recent trials and studies evaluating immunotherapeutic approaches in ovarian cancer.Results: Standard treatment for ovarian cancer includes cytoreductive surgery followed by platinum-based chemotherapy; however, recurrence and platinum resistance remain major clinical challenges. In recent years, immunotherapy has emerged as an actively investigated treatment strategy, particularly in platinum-resistant disease. Various strategies are under investigation, including immune checkpoint inhibitors, CAR T-cell therapies, and oncolytic viruses. PD-1/PD-L1 inhibitors have shown potential efficacy, especially in tumors expressing PD-L1, which may serve as a predictive biomarker for treatment response.Conclusions: Despite promising research results, the clinical benefits of immunotherapy in ovarian cancer remain limited. Future studies should focus on identifying reliable predictive biomarkers, optimizing combination therapies, and improving treatment efficacy while maintaining an acceptable safety profile.